Results 201 to 210 of about 198,722 (342)
Abstract Over recent years, several deep learning (DL) models have been presented to predict colorectal cancer (CRC) patient survival directly from haematoxylin and eosin (H&E)‐stained routine whole‐slide images (WSIs). Unlike traditional studies that rely on manually defined histopathological features, weakly supervised DL allows training directly on ...
Nic G Reitsam +23 more
wiley +1 more source
S100A8-associated inflammatory microenvironment is related to its cell-of-origin and potentiates BRAF inhibitor resistance in papillary craniopharyngioma. [PDF]
Zhao C +12 more
europepmc +1 more source
Evolving Features of RASopathies Among Pregnancies With Abnormal Fetal Fluid Collections
ABSTRACT Objective We aimed to characterize the fetal features across gestation and describe genotype‐phenotype correlations for pregnancies with fetal RASopathies that were more severely affected as they presented with at least one abnormal fluid collection.
Natalie B. Gulrajani +17 more
wiley +1 more source
Thermal ablation is increasingly used for selected benign and low‐risk thyroid nodules, yet some patients still require thyroidectomy for regrowth, persistent symptoms, or new oncologic concern. The surgical and pathological impact of ablation‐induced remodeling remains incompletely defined.
Daqi Zhang +7 more
wiley +1 more source
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. [PDF]
Kawczak P, Bączek T.
europepmc +1 more source
ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for malignant melanoma (MM). However, given variable response rates and potential toxicities, identifying robust biomarkers is crucial. We investigated whether the modified Glasgow Prognostic Score (mGPS) predicts treatment efficacy and toxicity in Asian patients with
Ken Horisaki +4 more
wiley +1 more source
The Emerging Melanoma Management: Historical Perspective to Future Directions. [PDF]
Hui SY +5 more
europepmc +1 more source

